Le Lézard
Classified in: Science and technology, Business
Subjects: TNM, ACC

Fastbase, Inc. (FBSE) Announces Plan to File Form 10 Registration Statement with SEC


NEW YORK, May 10, 2023 /PRNewswire/ -- Fastbase, Inc. (OTC: FBSE) announced today that its legal counsel has finalized the Form10  ? General Form of Registration of Securities in order for its subsidiary, Trustfeed Corp. (OTC: TRFE), to become fully reporting with the United States Securities and Exchange Commission ("SEC").  Trustfeed expects filing the Form10 with SEC in the coming days.

Rasmus Refer, CEO, Fastbase stated, "The planned Form 10 filing will provide investors with detailed information about Trustfeed, including an overview of its business strategies, risk factors, as well as audited financial statements.  We believe that this next step is fundamental to Trustfeed's efforts to provide transparency to shareholders and to bring additional focus upon Trustfeed from a large group of qualified investors and acquisition candidates."

Mr. Refer added, "With Fastbase being the majority shareholder of Trustfeed, Trustfeed attaining fully-reporting status is in line with the plans of both Fastbase and Trustfeed to pursue significant acquisitions in 2023.  Both companies plan to do stock-based acquisitions to improve revenues, strengthen market position, and create shareholder value. The growth of Trustfeed through any future acquisitions directly benefits Fastbase and its shareholders through the revenue stream generated by Trustfeed. We are already in communication with partners in the merger and acquisition sector."

Once the Form 10 is declared effective, Trustfeed will be required to meet SEC reporting requirements of filing quarterly reports on Form 10-Q and annual reports on Form 10-K, including audited financial statements, along with current reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act of 1934.

"By filing the Form10, we are our journey which we expect will eventually allow Trustfeed to be listed on a senior exchange and to provide the utmost transparency in the market, all of which brings added value to Trustfeed stock and, as a result of Fastbase owning approx. eighty percent of Trustfeed shares, added value to Fastbase and its own shareholders," said Rasmus Refer, Fastbase CEO.

About Fastbase, Inc.

Fastbase is a web and data company providing business insights on a large scale and offers a growing suite of business solutions to support B2B lead acquisition, marketing, and sales. Fastbase's international lead acquisitions suite gathers detailed information on website visitors for the past 24 months, including the name of the company, contact information, emails, and LinkedIn profiles.

Media Contact:
email: [email protected]  

SOURCE Fastbase, Inc.


These press releases may also interest you

at 11:10
Orion Health, a global leader in digital health solutions, announced today that it has been awarded partner status by Panda Health for its Orchestral Health Intelligence Platform, one of three pillars of the Unified Healthcare Platform. Panda Health...

at 06:13
eWTP Arabia Capital Technology Fund I ("Techology Fund I"), managed by eWTP Arabia Capital ("eWTPA"), one of the leading private equity firms in the Middle East, was listed in the Preqin League Tables as the the fifth top-performing VC funds in the...

18 mai 2024
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

18 mai 2024
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

18 mai 2024
"Maximizing customer retention and expansion is more important than ever for B2B SaaS companies," said Steven Forth, CEO of Ibbaka. "Our...

18 mai 2024
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: